Lepu Biopharma Co. Ltd. Class H (2157) Stock Statistics & Valuation Metrics

Lepu Biopharma Co. Ltd. Class H has a market cap or net worth of HK$9.93B. The enterprise value is HK$9.62B.

Lepu Biopharma Co. Ltd. Class H has 1,804,439,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lepu Biopharma Co. Ltd. Class H’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -21.47%.

The current PE Ratio of Lepu Biopharma Co. Ltd. Class H is ―. Lepu Biopharma Co. Ltd. Class H’s PEG ratio is -0.00593.

In the last 12 months, Lepu Biopharma Co. Ltd. Class H had revenue of 367.79M and earned -411.38M in profits. Earnings per share was -0.24.

In the last 12 months, operating cash flow was -81.26M and capital expenditures -20.76M, giving a free cash flow of -102.02M billion.

Lepu Biopharma Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Lepu Biopharma Co. Ltd. Class H upcoming earnings date is Apr 1, 2026, TBA (Confirmed).

Lepu Biopharma Co. Ltd. Class H as a current ratio of 0.62, with Debt / Equity ratio of 123.15%

In the past 12 months, Lepu Biopharma Co. Ltd. Class H has paid 0.00 in taxes.

Lepu Biopharma Co. Ltd. Class H EV to EBITDA ratio is -14.77, with an EV/FCF ratio of -17.85.

Lepu Biopharma Co. Ltd. Class H has HK$536.34M in cash and marketable securities with HK$917.81M in debt, giving a net cash position of -HK$381.47M billion.

Gross margin is 88.41%, with operating margin of -106.25%, and net profit margin of -111.85%.

The average price target for Lepu Biopharma Co. Ltd. Class H is HK$9.96, which is 11.43% higher than the current price. The consensus rating is Moderate Buy